The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.
Abstract
PURPOSE: This study sought to examine the prognostic role of p53 nuclear overexpression in muscle-invasive bladder cancer because of its correlation with progression of superficial bladder cancer. PATIENTS AND METHODS: Ninety of 111 patients treated with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) with a median follow-up duration of 5.8 years were evaluated. p53 nuclear overexpression was determined by immunohistochemistry on deparaffinized tissue sections. Patients were stratified into two groups according to the percent of tumor cells with positive nuclear reactivity. Overexpression was defined as tumors with > or = 20% cells with positive nuclear reactivity and nonoverexpression as tumors with less than 20% reactivity. RESULTS: Nuclear overexpression was observed in 47 patients and nonoverexpression in 43 patients. Patients whose tumors had p53 overexpression had a significantly higher proportion of cancer deaths. A multivariate analysis that evaluated the pretreatment variables p53 nuclear overexpression, age, sex, palpable mass, prechemotherapy tumor stage, performance status, ureteral obstruction, tumor size, multifocality, and grade showed that p53 overexpression had independent significance for survival (P = .001; relative risk ratio, 3.1). The impact of p53 overexpression on survival was predominantly in T2 and T3a tumors. Long-term survival was evident in seven of 17 patients (41%) with p53 overexpression versus 20 of 26 (77%) in whom p53 was not overexpressed (P = .007). CONCLUSION: p53 nuclear overexpression has independent prognostic value for survival in patients with invasive bladder cancer treated with neoadjuvant chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., & Levine, A. J. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.531 · Cited by 1,144
Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., & Wahl, G. M. (1992) · Cell · doi:10.1016/0092-8674(92)90244-7 · Cited by 1,089
Regulation of the specific DNA binding function of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 909
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 619
BANKS, L., MATLASHEWSKI, G., & CRAWFORD, L. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb09919.x · Cited by 495
Esrig, D., Spruck, C., Nichols, P. W., Chaiwun, B., Steven, K. E., Groshen, S. G., Chen, S. C., Skinner, D. G., Jones, P. A., & Côté, R. J. (1993) · PubMed Central · Cited by 452
Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder Cancer
Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W. R., Fuks, Z., & Reuter, V. E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.16.1251 · Cited by 334
Self-citationLipponen, P. K. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530304 · Cited by 253
Logothetis, C. J., Xu, H.-J., Ro, J. Y., Hu, S.-X., Sahin, A., Ordonez, N., & Benedict, W. F. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.16.1256 · Cited by 244
WALLACE, D. (1968) · American Journal of Roentgenology · doi:10.2214/ajr.102.3.581 · Cited by 215
Association of P53 Nuclear Overexpression and Tumor Progression in Carcinoma in situ of the Bladder
Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z.-F., Sheinfeld, J., Fair, W. R., Herr, H. W., & Reuter, V. E. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)32745-3 · Cited by 211
Self-citationAltered Patterns of MDM2 and TP53 Expression in Human Bladder Cancer
Lianes, P., Orlow, I., Zhang, Z.-F., Oliva, M. R., Sarkis, A. S., Reuter, V. E., & Cordon-Cardo, C. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1325 · Cited by 194
Self-citationDistinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage.
Spruck, C. H., Rideout, W. M., Olumi, A. F., Ohneseit, P. F., Yang, A. S., Tsai, Y. C., Nichols, P. W., Horn, T. D., Hermann, G. G., & Steven, K. E. (1993) · PubMed · Cited by 162
Splinter, T. A. W., Scher, H. I., Denis, L., Bukowski, R., Simon, S., Klimberg, I. W., Soloway, M. S., Vogelzang, N. J., van Tinteren, H., & Herr, H. W. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37318-4 · Cited by 128
Self-citationDalbagni, G. M., Presti, J. C., Reuter, V. E., Zhang, Z., Sarkis, A. S., Fair, W. R., & Cordon‐Cardo, C. (1993) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199300020-00002 · Cited by 95
Self-citationP53 NUCLEAR OVEREXPRESSION AND DISEASE PROGRESSION IN TA-BLADDER CARCINOMA
As, S., Zhang, Z., Cordon‐Cardo, C., Melamed, J., Dalbagni, G. M., Sheinfeld, J., Fair, W. R., Hw, H., & Reuter, V. E. (1993) · International Journal of Oncology · doi:10.3892/ijo.3.2.355 · Cited by 40
Self-citationPreemptive (neoadjuvant) chemotherapy for invasive bladder cancer: a decade of experience.
Raghavan, D., Pearson, B., Tynan, A., Wh, W., Wines, R. D., Rochford, M., Langdon, P., & Duval, P. (1990) · PubMed · Cited by 5
Cited by
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Bellmunt, J., Paz-Ares, L., Cuello, M., Cecere, F. L., Albiol, S., Guillem, V., Gallardo, E., Carles, J., Mendez, P., de la Cruz, J. J., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl435 · Cited by 319
P53 as a prognostic marker for bladder cancer: a meta-analysis and review
Malats, N., Bustos, A., Nascimento, C. M., Fernandez, F., Rivas, M., Puente, D., Kogevinas, M., & Real, F. X. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70315-6 · Cited by 317
Plimack, E. R., Hoffman-Censits, J. H., Viterbo, R., Trabulsi, E. J., Ross, E. A., Greenberg, R. E., Chen, D. Y. T., Lallas, C. D., Wong, Y.-N., Lin, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2465 · Cited by 287
PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE
STEIN, J. P., GROSSFELD, G. D., GINSBERG, D. A., ESRIG, D., FREEMAN, J. A., FIGUEROA, A. J., SKINNER, D. G., & COTE, R. J. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)62747-2 · Cited by 271
Metadata
- Authors
- Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F., Schultz, P. K., Cordon-Cardo, C., & Scher, H. I.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-06
- Volume
- 13
- Issue
- 6
- Pages
- 1384-1390
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2177584245
- Cited by
- 254
- References
- 24
- FWCI
- 12.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.